<div id="readability-page-1"><p>Federated Hermes Inc. decreased its stake in shares of  Fortrea Holdings Inc. (NASDAQ:FTRE - Free Report) by 78.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 85,564 shares of the company's stock after selling 317,297 shares during the period. Federated Hermes Inc. owned 0.09% of Fortrea worth $720,000 as of its most recent filing with the SEC.</p><p>Several other hedge funds have also recently bought and sold shares of FTRE. Brandes Investment Partners LP boosted its stake in shares of  Fortrea by 72.8% in the second quarter. Brandes Investment Partners LP now owns 224,272 shares of the company's stock valued at $1,108,000 after buying an additional 94,448 shares during the period.  Bank of Nova Scotia bought a new position in  Fortrea during the 2nd quarter worth $5,087,000.  Allianz Asset Management GmbH raised its holdings in  Fortrea by 335.1% in the 2nd quarter. Allianz Asset Management GmbH now owns 254,106 shares of the company's stock valued at $1,255,000 after acquiring an additional 195,706 shares in the last quarter.  Brighton Jones LLC acquired a new position in  Fortrea in the 2nd quarter valued at $156,000.  Finally, ProShare Advisors LLC bought a new stake in shares of  Fortrea during the 2nd quarter valued at $117,000. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of brokerages recently commented on FTRE. Robert W. Baird  set a $19.00 price target on Fortrea in a research report on Wednesday, January 14th. Wall Street Zen lowered shares of Fortrea from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 27th. Mizuho  set a $15.00 target price on shares of Fortrea in a research report on Friday, January 9th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Fortrea in a report on Thursday, January 22nd. Finally, Zacks Research cut shares of Fortrea from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 20th. Four equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average price target of $16.75.</p><p><b>Check Out Our Latest Stock Report on Fortrea</b></p><h2>Fortrea Price Performance</h2><p>FTRE stock opened at $14.65 on Friday. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -1.30, a P/E/G ratio of 0.40 and a beta of 1.59. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.00 and a quick ratio of 1.00. The company has a 50 day simple moving average of $16.37 and a 200 day simple moving average of $11.83. Fortrea Holdings Inc. has a 1 year low of $3.97 and a 1 year high of $18.67. </p><p>Fortrea (NASDAQ:FTRE - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.04). Fortrea had a positive return on equity of 5.64% and a negative net margin of 36.77%.The company had revenue of $701.30 million for the quarter, compared to the consensus estimate of $643.43 million.  Research analysts anticipate that  Fortrea Holdings Inc. will post 0.51 EPS for the current fiscal year. </p><h2>Fortrea Profile</h2> (Free Report)<p>Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific's Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company's comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.  </p><p>Fortrea's core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.</p><h2>Read More</h2><ul><li>Five stocks we like better than Fortrea</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>New gold price target</li></ul><p><strong>Want to see what other hedge funds are holding FTRE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc. (NASDAQ:FTRE - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlRSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlRSRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Fortrea Right Now?</h2><p>Before you consider Fortrea, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortrea wasn't on the list.</p><p>While Fortrea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Federated Hermes Inc. has reduced its stake in Fortrea Holdings Inc. (NASDAQ:FTRE) by 78.8%, selling 317,297 shares in the 3rd quarter, leaving it with 85,564 shares valued at $720,000. Other hedge funds have also adjusted their positions in FTRE. Analysts have mixed ratings on the stock, with an average rating of "Hold" and a price target of $16.75. Fortrea reported earnings of $0.12 per share, missing estimates, with revenue of $701.30 million for the quarter. The company specializes in contract development and manufacturing for the pharmaceutical industry.</p>

Market Beat

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Fortrea

iShares US Healthcare Providers

Health Care Select Sector SPDR

iShares US Medical Devices

SPDR S&P Biotech

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Federated Hermes Inc. Sells 317,297 Shares of Fortrea Holdings Inc. $FTRE